Rapport Therapeutics, Inc. Common Stock (RAPP) Financials

RAPP Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 459.0 million 36.1 million
March 31, 2026 497.6 million 26.1 million
Dec. 31, 2025 512.4 million 27.8 million
Sept. 30, 2025 535.3 million 23.7 million

RAPP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -41.5 million 7.2 million
March 31, 2026 -13.1 million 7.0 million
Dec. 31, 2025 -24.9 million 5.7 million
Sept. 30, 2025 -17.6 million 4.7 million

RAPP Net Income

No data available :(

RAPP Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 436.1 million - 10.1 million
March 31, 2026 476.8 million 8.2 million 2.6 million
Dec. 31, 2025 490.5 million 8.7 million 2.8 million
Sept. 30, 2025 513.0 million 9.4 million 2.5 million

RAPP Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 47.5 million
March 31, 2026 47.2 million
Dec. 31, 2025 47.0 million
Sept. 30, 2025 37.9 million

RAPP Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 78000 51.4 million 9.4 million -
March 31, 2026 86000 32.7 million 11.5 million -
Dec. 31, 2025 169000 30.3 million 8.3 million -
Sept. 30, 2025 134000 22.3 million 7.7 million -

RAPP Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 20.0 million 227000
Dec. 31, 2025 - 265000
Sept. 30, 2025 - 256000

RAPP

Price: $48.26

52 week price:
13.62
49.50

Earnings Per Share: -2.96 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 2.3 billion

Links: